Bristol-Myers Squibb (IT:1BMY)
:1BMY
1BMY Stock Chart & Stats
€50.11
€0.63(1.16%)
At close: 4:00 PM EST
€50.11
€0.63(1.16%)
Day’s Range― - ―
52-Week Range€33.00 - €55.00
Previous CloseN/A
Volume0.00
Average Volume (3M)67.00
Market Cap
€103.84B
Enterprise Value€158.04B
Total Cash (Recent Filing)€10.67B
Total Debt (Recent Filing)€47.14B
Price to Earnings (P/E)15.6
Beta0.31
Next Earnings
Apr 30, 2026EPS Estimate
1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.08
Shares Outstanding2,036,473,800
10 Day Avg. Volume58
30 Day Avg. Volume67
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.96
Price to Sales (P/S)2.28
P/FCF Ratio8.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€53.36Price Target Upside6.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
EPS Forecast (FY)5.36
Revenue Forecast (FY)€40.22B
Bulls Say, Bears Say
Bulls Say
CELMoD Clinical EfficacyAnalyst notes Phase III EXCALIBER-RRMM showed a statistically significant improvement in minimal residual disease negativity for iberdomide plus Darzalex, indicating meaningful disease control that could support broader adoption of CELMoD therapies.
Eliquis Pricing Boost And GuidanceAnalyst points out that one-time US pricing adjustments removed certain rebate and penalty liabilities for the leading anticoagulant, lifting revenue expectations and underpinning guidance that exceeded consensus.
Regulatory Momentum For IberdomideAnalyst highlights that the FDA accepted the NDA for iberdomide using minimal residual disease as an endpoint and granted breakthrough therapy designation, signaling regulatory recognition that could expedite market access if approval is secured.
Bears Say
Approval Risk Tied To Survival DataAnalyst warns that overall survival and confirmatory outcomes remain pending, creating uncertainty about converting accelerated approvals into full approvals and the drug's ultimate commercial impact.
Clinical Safety And Tolerability ConcernsAnalyst cautions that choosing a lower iberdomide dose suggests potential toxicity issues, with prior neutropenia observations that could limit tolerability and constrain real-world use.
Loss Of Exclusivity And Generic ErosionAnalyst notes that the leading anticoagulant will face generic competition when exclusivity ends, posing a significant revenue erosion risk for the company.
Bristol-Myers Squibb News
1BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was €33.00 and its highest was €55.00 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is €103.84B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Apr 30, 2026 which is in 20 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Feb 05, 2026. The company reported €1.078 earnings per share for the quarter, beating the consensus estimate of €1.048 by €0.029.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb does not currently pay dividends.
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.23.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,036,473,800 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of €1.078 in its last earnings report, beating expectations of €1.048. Following the earnings report the stock price went up 1.014%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in IT:1BMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€53.36 (6.48% Upside)
€53.36 (6.48% Upside)
Blogger Sentiment
Bullish
IT:1BMY Sentiment 92%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.12%
12-Months-Change
Fundamentals
Return on Equity
39.27%
Trailing 12-Months
Asset Growth
-2.77%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
1BMY Company Deck
1BMY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial positive momentum: a high-growth portfolio delivering double-digit growth, multiple products achieving billion-dollar status, a robust near-term pipeline with numerous data catalysts, disciplined cost savings, and a strengthened balance sheet. Offsetting risks include LOE/generic pressures on the legacy portfolio (notably Eliquis over time), mix-driven margin pressure, one-time R&D charges, and the execution risk inherent in upcoming clinical readouts. Overall, the positives (strong commercial growth, pipeline depth, cost execution, and financial flexibility) outweigh the challenges.View all IT:1BMY earnings summaries1BMY Revenue Breakdown
54.80% Growth Portfolio
45.20% Legacy Portfolio
1BMY Stock 12 Month Forecast
Average Price Target
€53.36
▲(6.48% Upside)
Technical Analysis
Options Prices
Currently, No data available
---